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Abstract 
Background and aims 
The United Kingdom’s National Institute for Health and Care Excellence guidance (NICE PH48) 
recommends that pharmacotherapy combined with behavioural support be provided for all smokers 
admitted to hospital; however, relapse to smoking after discharge remains common. This study 
aimed to assess the effect of adding home support for newly-abstinent smokers to conventional 
NICE-recommended support in smokers discharged from hospital. 
 
Design 
individually-randomised parallel group trial.  
 
Setting 
One UK acute hospital. 
 
Participants 
404 smokers aged >18 admitted to acute medical wards between June 2016 and July 2017 were 
randomised in equal numbers to each treatment group. 
 
Interventions and comparators 
The intervention provided 12 weeks of at-home cessation support which included help in 
maintaining a smoke-free home, help in accessing and using medication, further behavioural support 
and personalised feedback on home air quality.  The comparator was NICE PH48 care as usual. 
 
 
Measures 
The primary outcome was self-reported continuous abstinence from smoking validated by an 
exhaled carbon monoxide level <6ppm four-weeks after discharge from hospital. 
 
Findings 
In an intention-to-treat analysis at the four-week primary endpoint, 38 participants (18.8%) in the 
usual care group and 43 (21.3%) in the intervention group reported continuous abstinence from 
smoking (odds ratio 1.17, 95% confidence interval 0.72 to 1.90, Bayes factor 0.33). There were no 
significant differences in any secondary outcomes, including self-reported cessation at 3 months, 
having a smoke-free home, or number of cigarettes smoked per day in those who did not quit. 
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Conclusions 
Provision of a home visit and continued support to prevent relapse to smoking after hospital discharge 
did not appear to increase subsequent abstinence rate above usual care in accordance with UK 
guidance from the National Institute of Health and Care Excellence.  
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Introduction 
Tobacco smoking is the largest avoidable cause of premature death and disability in the UK(1). Half of 
all lifelong smokers die as a consequence of their smoking, typically from lung cancer, chronic 
obstructive pulmonary disease or cardiovascular disease (2). Average life expectancy among smokers 
is 10 years less than in never-smokers, equivalent to nearly 3 months of life lost for every year smoked 
after the age of 35 (2, 3). Quitting smoking at almost any age significantly increases both expectancy 
and quality of life (2). Helping as many as possible of the more than 7 million current smokers in the 
UK (4)  to quit smoking is therefore one of the highest public health priorities, and also one of the most 
cost effective of medical interventions(5). Doing so would also help save the UK National Health 
Service around £1 billion in health care costs each year(6). 
 
Every year an estimated 1.1 million smokers are admitted to English hospitals (7) and every one of 
these admissions represents a prime opportunity to intervene to promote smoking cessation, 
particularly since most smokers abstain from smoking while in hospital (8). Recent NICE guidance 
(PH48)(9) recommends that smoking cessation interventions should be provided in routine care 
pathways for all smokers admitted to hospital, and our earlier work has demonstrated that default 
delivery of cessation support to all smokers significantly increases uptake of support and doubles the 
proportion of smokers who quit long term (10).  
 
Smoking cessation interventions are well established and usually consist of behavioural support 
delivered either face-to-face or over the telephone, and pharmacotherapies (11-19). A systematic 
review of 50 studies by Rigotti and colleagues found that high intensity behavioural interventions that 
are initiated during hospital admission and include at least one month of supportive contacts increases 
smoking quit rates at six months of beyond, and adding NRT increased quit rates further (20), though 
the authors did not find any effect for less intensive interventions, or for adding varenicline or 
bupropion to behavioural support. In our study, among smokers who received care similar to that now 
recommended by NICE, 62% of those who were abstinent at discharge had relapsed by four weeks, 
and 81% by 6 months (10).   Two studies in the US tested a post-discharge smoking cessation support 
package which included automated interactive voice telephone calls and stop smoking medications 
for three months after discharge. The first study allowed participants the option of a telephone call 
from a live tobacco counsellor, and reported that quit rates were significantly higher in the 
intervention group at one month and six months (though not at three months)(21).  The latter study 
utilised a telephone quitline in place of a live counsellor and found that quit rates were significantly 
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higher in the intervention group for the duration of treatment (one and three months) but this effect 
was no longer significant after six months (22).  
 
Evidence suggests that intensive interventions to support smoking cessation after discharge from 
hospital have potential to increase quit long term quit rates, but there is still potential to increase 
these further.  To our knowledge, no study to date has investigated providing a home visit after 
discharge from hospital to support the transition from temporary abstinence to the home 
environment. We therefore aimed to test, as an extension to our hospital inpatients study (10), the 
effectiveness of an intensive home support intervention for newly-abstinent smokers delivered within 
24 hrs of hospital discharge and maintained for up to 12 weeks post discharge. 
 
Methods 
Trial design and participants 
We used a parallel group individually randomised study design.  Eligible participants comprised all 
patients aged over 18 years admitted for at least 24 hours to one of the 18 acute medical wards at a 
large UK teaching hospital (Nottingham City Hospital) who were ascertained to be current smokers, 
lived within a 40 mile radius of the hospital, were able to provide informed consent and were not 
pregnant. Recruitment ran from 28 June 2016 to 28 July 2017. The trial was registered with ISRCTN 
31 May 2016 (ISRCTN10774163) and activated with the National Institute for Health Research in 
April 2016.   
 
Procedures 
All patients admitted to acute medical wards 
Smoking cessation practitioners (SCPs) visited each participating hospital ward on every weekday to 
ascertain the smoking status of all newly admitted patients, either from a checklist completed on the 
paper admission proforma for each patient or, in absence of clear documentation, by questioning 
the patient directly. Specialisms of wards included cardiac (n=4), respiratory (n=4), oncology (n=2), 
stroke (n=2), thoracic (n=1), renal (n=1), infectious disease (n=1), pre-operative (n=1); the remaining 
two wards were ‘overspill’ wards for the above specialisms that opened at times of increased 
capacity.  Enforcement of hospital smoke free policy was variable across wards.  Patients were 
categorised as current smokers if they answered ‘yes’ to the question ‘Do you smoke?’ or if they 
answered ‘no’, but reported that they had smoked in the seven days before admission. Regardless of 
desire to quit smoking after discharge, all current smokers were offered smoking cessation 
pharmacotherapy and behavioural support as recommended for secondary care settings in NICE 
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PH48 guidelines (9), which in brief comprised: one-to-one behavioural counselling delivered at the 
bedside by SCPs trained to National Centre for Smoking Cessation and Training standards (23); and 
either dual nicotine replacement therapy comprising a long-acting transdermal nicotine patch in 
conjunction with a short-acting preparation (inhalator, gum or lozenge) or therapy with varenicline 
or buproprion. Further daily behavioural support was offered to each patient by the SCP and 
delivered as often as accepted by the patient throughout admission. Current smokers who were 
eligible for inclusion in the trial were also given a patient information sheet describing the trial, and 
visited 24 hours later by a researcher who provided further information as required and requested 
written consent. All consenting participants completed a baseline questionnaire and where possible 
provided an exhaled Carbon Monoxide (CO) measurement, and for the remainder of their admission 
received  cessation support in accordance with NICE PH48 guidelines (9). SCPs and other members of 
the research team liaised with patients and clinical staff to ascertain likely discharge dates so that all 
participants could, where possible, be visited on the day of discharge or on the Friday immediately 
before a planned weekend discharge, ensuring that smokers in both groups had received NICE PH48 
care (including two weeks’ supply of NRT or pharmacotherapy to take home on discharge). In order 
to be enrolled in the trial, patients must have been attempting to remain abstinent throughout their 
admission (though lapses did not preclude participation) and be willing to attempt continued 
abstinence after discharge. 
 
Randomisation and masking 
Consenting participants were individually randomised, using concealed allocation, to receive either 
usual care or the intervention. The randomisation sequence (1:1 in permuted blocks of random size 
up to size six) was generated using a computer random number generator and patients were 
allocated sequentially. Randomisation was conducted independently by the University of 
Nottingham Clinical Trials Unit and delivered by the research team. The trial interventions were 
necessarily open in design, so research staff delivering the interventions and collecting follow up 
data were not blind to participant allocation. However all analysis and work of the trial steering 
group were carried out blind to treatment allocation. According to the randomisation, participants 
then received usual care or the intervention package described below. 
 
Data collection 
In both treatment groups, baseline demographic data including smoking behaviour (which included 
information about who smoked in the home), advice delivered and /or NRT received in hospital were 
collected face to face at the bedside by the researcher during the initial admission to 
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hospital.  Follow up data were collected at 4 and 12 weeks after discharge from hospital either in 
face to face or telephone contact by the research team and included information on hospital 
readmissions, quit attempts and general smoking behaviour including smoking behaviour at home, 
type of help used to support quit attempt.  Participants were contacted a maximum of three times 
by telephone at various times in the ‘working-day’ then by text and finally by letter in an attempt to 
collect follow up data. All members of the research team were trained in Good Clinical Practice and 
informed consent. 
 
Usual Care 
On the day of or the day before discharge, or on the first working day after unplanned discharge, the 
research team referred those participants to usual care directly to their local stop smoking 
service (LSSS) for further cessation support after discharge. The support provided varied between 
LSSS but typically comprised behavioural support from a NCSCT-trained community SCP either face-
to-face or in a group in a health or community setting, or delivered by telephone, and continued 
pharmacotherapy provided, on request, by the LSSS or participants’ general practitioner (GP)  (23, 
24). Participants were not offered electronic cigarettes but were free to use their own e-cigarette to 
support their quit attempt alongside or instead of prescribed pharmacotherapy. Participants were 
contacted by telephone by the research team at 4 and 12 weeks after discharge and asked to 
complete a short questionnaire describing their quit experience (products used, support received 
and number of other smokers in the household) and report their smoking status. If patients reported 
abstinence from smoking in line with the Russell Standard (25) a researcher visited the patient at 
home, work or in a convenient community setting to validate smoking status by measuring exhaled 
CO.  
 
Intervention 
On the day of or the day before discharge, or on the first working day after unplanned discharge, the 
SCP arranged to visit the patient at home, where possible between 24 and 48 hours after discharge. 
Those patients who did not want to be visited within this timescale were offered further telephone 
support with arrangements made to visit the home as soon as acceptable to the participant. The SCP 
offered one-to-one counselling, delivered at the discretion of the patient and usually weekly, but not 
less than once a fortnight, which included  discussing the benefits of removing smoking 
paraphernalia from the home, discussions around feelings about smoking, managing high risk 
situations and maintaining changes to smoking habits for up to 12 weeks. During the home visits, 
SCPs also discussed quitting with other family members who were present, identified themselves as 
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smokers and expressed a desire to quit; provided an explanation and (if appropriate) a 
demonstration of how to use cessation pharmacotherapy; and, if accepted, referred the person to 
the LSSS or directed towards smoke-free websites and mobile phone apps which may have been 
helpful. Personalised feedback on home air quality was provided through 24 hour sampling using a 
Sidepak Aerosol Monitor AM510 (TSI Instruments Ltd, High Wycombe, UK), positioned in the main 
living area to measure concentrations of PM2.5.  The research team converted data collected during 
the three periods of air quality measurement (baseline, week 7 and week 12) into a graphical format 
that could be easily explained to the participant immediately after each measurement period, 
relating the information to the WHO recommended 24 hours of PM2.5 concentrations below 
25 µg/m3 per 24-hour period(26). Participants were shown the graphs with attention drawn to 
periods of time that showed particularly high or low SHS exposure in the home, supported by 
the discussion of reasons for high or low values and of strategies to reduce exposure both in general 
and during periods when levels were particularly high.  
 
Participants who experienced problems with or for any reason were not using their cessation 
pharmacotherapy were offered alternatives. SCPs also provided text and telephone support to 
participants at times of relapse risk, or in the event of relapse, were available for contact at any time 
during office hours. Patients were directed towards to websites and smart phone apps designed to 
support quitting.  Any participant who relapsed to smoking during the 12-week intervention period 
was encouraged to make another quit attempt with support of the SCPs.  
 
E-cigarettes were not provided as part of the trial, but patients who wished to purchase or use their 
own e-cigarette were advised to do so in line with the NCSCT guidelines for e-cigarettes (27), and 
their use was incorporated into the patients’ quit plan. Air monitoring as a marker for second hand 
smoke, supplemented with discussions of the dangers of second-hand smoke (28, 29) was offered at 
the initial home visit and again after four weeks to those patients who admitted to smoking indoors 
or who had cohabitees who smoked indoors. Cessation support was offered for a total of 12 weeks. 
Cessation outcome data, with CO validation if appropriate, were collected as in the usual care group, 
but intervention participants were also asked questions about the components of the intervention 
as part of the 12 week questionnaire. 
 
 
Outcome measures:  
 9 
The primary outcome was self-reported continuous abstinence from smoking validated by an 
exhaled carbon monoxide level <6ppm at four weeks after discharge from hospital. Secondary 
outcomes included self-reported and validated continuous abstinence from smoking at three 
months after discharge from hospital, self-reported reduction in cigarette consumption at four 
weeks after discharge smoking, self-reported presence of a smoke free home baseline four weeks 
and three months post-discharge from hospital, changes in maximum concentrations of PM2.5 in 
indoor air and the proportion of time PM2.5 concentrations exceed WHO recommended safe levels 
of maximum exposure of 25 µg/m3 per 24-hour period at 24-48 hours, four weeks and three months 
post-discharge from hospital, and utilisation of each component of the complex intervention 
measured through participant self-report at four weeks and three months after discharge from 
hospital. 
 
Statistical analysis 
The primary analysis was by intention to treat and included all participants randomised to usual care 
or intervention. For smoking cessation outcomes it was assumed that participants who did not 
provide data at four weeks or three months, or those who did not provide an exhaled CO reading for 
validation of cessation, continued to smoke (25). It was also assumed that there was no change in 
the number of cigarettes smoked per day by these participants. A descriptive comparison of baseline 
characteristics was made between those randomised to intervention and usual care, and  
comparison of baseline characteristics of those who provided outcome data and those who did not 
was used to explore the pattern of missingness.  
 
We estimated the effect of the intervention on our primary outcome by comparing CO-validated 
four-week cessation between the intervention and the usual care groups using unadjusted logistic 
regression, stating the odds ratios and risk differences (estimated using the adjRR post-estimation 
command in Stata) with their 95% confidence intervals. Logistic regression was also used for binary 
secondary outcomes. Linear regression was used to determine the effect of the intervention on the 
self-reported number of cigarettes smoked per day by participants who were not abstinent from 
smoking four weeks after discharge, with adjustment for baseline cigarette consumption. This 
outcome variable was log transformed with results presented as the ratio of cigarettes smoked in 
the intervention group compared to usual care. For the primary and secondary outcomes, we carried 
out sensitivity analyses adjusting for baseline covariates of prognostic importance including  
cohabitation with a smoker, deprivation index, heaviness of smoking index as these have been 
identified as the most important factors for cessation in previous literature (30-32).   
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In a further sensitivity analyses, we additionally adjusted for whether the participant had been 
readmitted to hospital during the four weeks after the primary discharge.  We explored whether 
allowing for clustering by hospital ward affected the results for our primary outcome by fitting 
hospital ward as a random effect into our primary analysis. We also imputed missing values for CO 
readings using predictive mean matching imputation (drawing from the 5 closest observations) and 
we imputed missing values for smoking status using logistic regression imputation. This was 
repeated 20 times.  Unadjusted logistic regression was carried out on each of the 20 observations 
and the results were combined using MI procedures in Stata.  We also compared self-reported 
smoking at four weeks between participants who did and did not take part in the trial to determine 
which group was more or less likely to quit. All analyses were conducted in STATA 14. The study 
sample size of 400 participants was calculated a priori to provide 90% power to detect a 16 
percentage point increase (from 38% to 54%) in CO-validated cessation at four weeks in the 
intervention group relative to the usual care group.  
 
 
Results 
Recruitment and participant flow during trial 
We assessed a total of 13 443 patients admitted to Nottingham City Hospital between 28 June 2016 
and 28 July 2017 (Figure 1). Of these, 10,366 (77%) ascertained to be non-smokers and 945 (7%) in 
whom we were unable to ascertain smoking status were excluded. A further 237 patients (2%) who 
did not meet other study entry criteria were also excluded (Figure 1). A total of 969 patients (7%) 
accepted advice to quit but declined to participate in the trial, while 522 (4%) declined advice and 
participation. A total of 404 patients (3% of all screened admissions and 19% of all ascertained 
smokers) were randomised, 202 to the intervention and 202 to usual care (Figure 1).  
 
Figure 1: CONSORT diagram of study recruitment and participation (33)   
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Characteristics of participants 
Participants were of mean (Standard Deviation (SD)) age 55 (15) years; 60% were male and over 60% 
were in the two most deprived quintiles of the general population (Table 1). Most (85%) were 
emergency (unplanned) admissions. Participants in both groups smoked a median of 15 (range 10 to 
20) cigarettes per day, and more than half had less than moderate scores on the Heaviness of 
Smoking Index. There were no marked differences in baseline characteristics between participants 
randomised to intervention or usual care groups, though the usual care arm had a higher proportion 
of people who were more heavily smoking dependent and lower proportion of smokers who had 
smoked for more than 41 years (Table1).  
 
 
Table 1: Participant Characteristics and Background summary table 
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Characteristic  Total Usual Care Intervention 
 404 202 202 
Age (Years)    
Mean (SD) 54.77 (14.50) 55.58 (13.82) 53.96 (15.11) 
Gender    
Female N (%) 158 (39.11) 86 (42.57) 72 (35.64) 
Male N (%) 246 (60.89) 116 (57.43) 130 (64.36) 
Ethnic group    
White British (%) 372 (92.08) 189 (93.56) 183 (90.59) 
White Other* (%) 15 (3.71) 6 (2.98) 9 (4.46) 
Other† (%) 11 (2.72) 3 (1.50) 8 (3.96) 
Unknown (%) 6 (1.49) 4 (1.96) 2 (0.99) 
Multiple deprivation index rank    
1 – most deprived(%) 168 (42.00) 82 (41.21) 86 (42.79) 
2 (%) 85 (21.25) 47 (24.62) 38 (18.91) 
3 (%) 60 (15.00) 31 (15.58) 29 (14.43) 
4 (%) 42 (10.50) 19 (9.55) 23 (11.44) 
5 – least deprived (%) 45 (11.25) 20 (10.05) 25 (12.44) 
Reason admitted to hospital    
Elective surgery N (%) 58 (14.36) 26 (12.87) 32 (15.84) 
Emergency N (%) 340 (84.16) 172 (85.15) 168 (83.17) 
Routine care N (%) 3 (0.74) 3 (1.47) 0 
Other N (%) 3 (0.74) 1 (0.49) 2 (0.99) 
Number of other people living in the house     
Adults    
Mean (SD) 0.88 (0.92) 0.86 (0.89) 0.90 (0.95 
Children     
Mean (SD) 0.44 (0.99) 0.41 (0.93)  0.47 (1.05) 
Qualification    
None N (%) 163 (40.35) 84 (41.58) 79 (39.11) 
GCSEs N (%) 117 (28.96) 45 (22.28) 72 (35.64) 
A-levels/AS-levels N (%) 44 (10.89) 23 (11.39) 21 (10.40) 
Degree N (%) 38 (9.41) 23 (11.39) 15 (7.43) 
Other (%) 42 (10.40) 27 (13.37) 15 (7.43) 
No of cigs daily before admission     
Median (IQR) 15 (10-20) 15 (10 - 20) 15 (9–20) 
Heaviness of smoking index    
Very low dependence (%) 139 (35.10) 60 (30.30) 79 (39.90) 
Low to moderate dependence (%) 119 (30.05) 59 (29.80) 60 (30.30) 
Moderate dependence 94 (23.74) 48 (24.24) 46 (23.23) 
High dependence 44 (11.11) 31 (15.66) 13 (6.57) 
Years smoking    
<1  1 (0.26) 0 1 (0.52) 
1 - 10  25 (6.53) 8 (4.19) 17 (8.85) 
11 - 20 53 (13.84) 23 (12.04) 30 (15.63) 
21 -40 146 (38.12) 76 (39.79) 70 (36.46) 
41 + 158 (41.25) 84 (43.98) 74 (38.54) 
Live with other smokers    
Yes 144 (37.11) 77 (40.10) 67 (34.18) 
No 244 (62.89) 115 (59.90) 129 (65.82) 
Readmission status    
Readmitted to hospital between baseline and 4 weeks post discharge  43 (10.64) 18 (8.91) 25 (12.38)  
Readmitted to hospital between baseline and 3 months post discharge 69 (17.08) 31 (15.35) 38 (18.81) 
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* White – Irish and European 
†Mixed White and Black Carribean, Mixed White and Black African, Asian/Asian British Indian, Asian/Asian British Pakistani, 
Black/Black British Carribean, Black/Black British African, Any Other Ethnic Group 
 
Participants in the Intervention group were more likely to accept behavioural support (OR 10.87, 
95% CI 4.21 to 28.08 (P<0.001)) in comparison to those in the usual care arm.  An offer of NRT was 
more common in the intervention arm(P=0.02), though there was a higher instance of missing data 
(whereby there was no clear description of whether NRT was offered or not in the clinical notes).  
Acceptance of NRT did not vary between the two groups (OR 1.13, 95%CI 0.67 to 1.93). (Table 2). 
 
Table 2: Acceptance of smoking cessation support  
 
 Total Usual Care Intervention Unadjusted 
OR (95% CI) 
[P-value] 
Accept behavioural support 404 202 202  
   Yes n (%) 351 (86.88) 157 (77.72) 194 (96.04) 10.87 
(4.21,28.08) 
[p<0.01] 
   No n (%) 49 (12.13) 44 (21.78) 5 (2.48) 1 
Unknown n (%) 4 (0.99) 1 (0.50) 3 (1.49)  
Offered NRT 351 157 194 
 
 
   Yes n (%) 323 (92.02) 
 
148 (94.27) 
 
175 (90.21) 
 
[p=0.02] 
 
   No n (%) 5 (1.42) 
 
5 (3.18) 
 
0  
   Unknown n (%) 23 (6.55) 4 (2.55) 19 (9.79)  
Accepted NRT  148 175  
   Yes n (%) 244 (75.54) 
 
109 (73.65) 
 
135 (77.14) 
 
1.13 
(0.67,1.93) 
[p=0.63] 
   No n (%) 71 (21.98) 34 (22.97) 37 (21.14)  
   Unknown n (%) 8 (2.48) 5 (3.38) 3 (1.72)  
 
 
Primary outcome 
At four weeks after discharge from hospital, 68 participants in the usual care group and 54 in the 
intervention group did not provide outcome data, for reasons including withdrawal from the study, 
non-response to contact, and death (Figure 1). Of all randomised participants, 38 (18.8%) in the 
usual care group and 43 (21.3%) in the intervention group reported continuous abstinence from 
smoking which was validated by an exhaled CO of less than 6 ppm  (Table 2). The relative odds of 
cessation at four weeks did not differ between groups either before (Odds Ratio (OR) 1.17, 95% 
Confidence Interval (CI) 0.72 to  1.90) or after (OR 0.95, 95% CI 0.56 to 1.62)  adjustment for  
baseline covariates and additionally readmission to hospital during these four weeks, which occurred 
in 18 (8.9%) usual care and 25 (12.4%) intervention group participants (Table 2). There was also no 
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substantial change in the odds of validated abstinence after allowing for potential clustering by ward 
(OR 1.19, 95% CI 0.72 – 1.98).  One hundred and forty seven participants in the intervention group 
accepted a home visit, of which 67 were visited within 24-48 hours and 80 were seen outside of this 
time; there was no difference in quit rates between these groups (p=0.31). 
 
Secondary outcomes 
There was no significant difference between treatment groups for secondary outcomes (Table 3). 
Self-reported abstinence at one and three months, and self-reported establishment of a smoke-free 
home were all  slightly but not significantly higher in the intervention group, but for three months 
abstinence the CO-validated proportions were almost identical (14.4% in the usual care and 13.9% in 
the intervention group). Adjustment for baseline covariates and additionally for  readmission to 
hospital during the three-month period (which occurred in 31 (15.4%) usual care and 38 (18.8%) 
intervention participants) had no appreciable effect on these differences.  
 
A higher proportion of self-reported quitters failed to validate their quit status in the intervention 
group than usual care at three months. Of 14 participants in the intervention group who were not 
CO validated quitters, three did not provide a CO reading and 11 had CO readings above 6ppm (26% 
of self reported quitters). In contrast, of three participants in the usual care group who were not CO 
validated quitters, two did not provide a CO reading and one had CO readings above 6ppm (3% of 
self reported quitters). 
  
Table 3: Trial effectiveness summaries: Four week and three month comparison by treatment arm 
(Odds Ratio) 
 
 Usual Care 
Group  
Intervention 
Group  
Unadjusted Adjusted 
model 1† 
Adjusted 
model 2 ‡ 
 
  
Odds ratio 
(95% CI) 
[P-value] 
Odds ratio 
(95% CI) 
[P-value] 
Odds ratio 
(95% CI) 
[P-value] 
Total 202 202 404 392 277 
Continuous smoking 
cessation, validated at 
4 weeks* 
38 (18.81%) 43 (21.29%) 1.17 
(0.72, 1.90) 
[0.53] 
1.05  
(0.64, 1.73) 
[0.84] 
0.95 
(0.56, 1.62) 
[0.85] 
Self-reported 
continuous smoking 
cessation (4 weeks) 
50 (24.75%)   55 (27.23%) 1.14  
(0.73, 1.78) 
[0.57] 
 
1.11 
(0.70, 1.75) 
[0.66] 
0.99 
(0.60, 1.63) 
[0.97] 
Self-report having a 
smoke-free home (4 
weeks) 
92 (45.54%) 102 (50.50%) 1.22  
(0.83, 1.80) 
[0.32] 
1.11 
(0.72, 1.70) 
[0.64] 
1.06  
(0.69, 1.64) 
[0.78] 
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Self-reported 
continuous smoking 
cessation (3 months) 
32 
(15.84%) 
  42 
(20.79%) 
1.39 
(0.84, 2.32) 
[0.17] 
1.32 
(0.78, 2.22) 
[0.30] 
1.31  
(0.74, 2.32) 
[0.35] 
Continuous smoking 
cessation, validated at 
3 months * 
29 
(14.36%) 
  28 
(13.86%) 
0.96  
(0.55, 1.68) 
[0.89] 
0.86 
(0.49, 1.53) 
[0.67] 
0.81  
(0.44, 1.50) 
[0.51] 
* Validated by exhaled CO less than 6ppm 
† Adjusted for co-habitation with a smoker status, deprivation index & heaviness of smoking index  
‡ Adjusted for readmission status, cohabitation with a smoker status, deprivation index & heaviness of smoking index 
 
 
 
The self-reported number of cigarettes smoked by participants who were not abstinent at four week 
decreased in both usual care and intervention from a median of 15 (range 10-20) to 6.5 (range 0-15) 
and  from a median of 15 (range 9-20) to 3 (range 0-10) respectively, but again, this difference was 
not significant either before or after adjustment  for baseline covariates.  
 
An average of 10 behavioural support sessions (SD 4.64) per participant were arranged by the 
research team, of which an average of 4.69 (SD 1.99) and 7.43 (SD 4.39) sessions were attended 
within the first four weeks after discharge and in total, respectively.  The choice of home visit or 
telephone contact was dictated by the participant.  Participants received, on average, 3.84 (SD 3.30) 
weeks’ supply of NRT and 30 (14.85%) received at least four weeks of NRT.  Contact with participants 
lasted for a median of 5.86 weeks (IQR 2.86-9.71 weeks) and 134 participants (66.3%) received more 
than the recommended four weeks of smoking cessation support.  All advisors adhered to the NCSCT 
standard treatment programme as a guideline for the 12-week duration (34).  Measures of uptake 
and perceived helpfulness of trial components among intervention group participants are 
summarised in Table 4. Both home visits and follow-up behavioural support  (face-to-face or 
telephone) were accepted by and delivered to over 70% of participants, and supportive phone call 
texts and nicotine replacement therapy by over 50%. These components were considered helpful by 
a majority of participants. Uptake of referral to LSSS was very low at less than 2%.  
 
 
Table 4: Adherence to and helpfulness of intervention components at three months (intervention 
group only) 
 
 Used at least 
once during 
trial(%) 
Participants reporting 
the component as 
useful* (%) 
Received behavioural support 97 (79.51%) 61 (62.89%) 
Home visit 89 (72.95%) 64 (71.91%) 
Nicotine Replacement Therapy 69 (56.56%) 47 (68.12%) 
 16 
Supportive phone calls texts 69 (56.56%) 37 (53.62%) 
Support to make home Smoke-Free 25 (20.49%) 13 (52.00%) 
Air quality feedback 20 (16.39%) 14 (70.00%) 
Information on E-Cigarettes 16 (13.11%) 7 (43.75%) 
Advice given to other smokers about quitting** 12(9.84%) 4 (33.33%) 
Signposting to websites 12 (9.84%) 2 (16.67%) 
Signposting to phone apps 12 (9.84%) 2 (16.67%) 
Referral to local SSS 2 (1.64%) 0 (0%) 
*In those using the component 
** To family, carers, others. 
 
Comparison of self-reported smoking status at week four between trial participants and patients 
who consented to provide follow-up data but declined trial participation indicates that the non-
participants were more likely to quit (45 of 114 (39.5%) reported they had quit at four weeks)  than 
trial participants (105 of 404 (26.0%) had quit) This difference was evident both before and after 
adjustment for Heaviness of Smoking Index (adjusted OR 1.94 (95% CI 1.12 to 3.34), p=0.019).  
 
Discussion 
This study demonstrates that smoking cessation treatment delivered in accordance with NICE PH48 
guidance (9) to inpatients in an acute UK hospital is not enhanced by adding a package involving a 
home visit after discharge to encourage compliance, assist in creating a smoke-free home or other 
initiatives intended to enhance treatment compliance and support sustained cessation after 
discharge. The study builds on our own (10) and others’ (35) work demonstrating that systematic 
intervention to support cessation in hospital inpatients is effective, and this approach was 
incorporated into current NICE guidance recommending that all in-patient smokers receive 
behavioural support and pharmacotherapy while in hospital, and receive follow up, for at least four 
weeks, after discharge (9). Our aim was to reduce the proportion of smokers who relapse to smoking 
within the first month  after discharge, which even in those receiving the systematic cessation 
intervention exceeded 60% (10).  
 
The relapse rate in both our trial groups was similar, and at around 80% was markedly higher than in 
the intervention group in our earlier study (10) and also higher than that achieved at six months in 
the observational evaluation of the Ottawa smoking cessation model (35). In contrast, the 
approximately 60% relapse rate among patients who received the usual care (NICE PH48) 
intervention and provided follow-up data without participating in the trial was similar to that 
observed in the group receiving an equivalent  intervention in our earlier work (10). There are no 
obvious explanations for these discrepancies, but their existence suggests that quit rates differ 
markedly between patients with different levels of motivation to participate in formal trials. It may 
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be the case that those who declined support and participation in the study had higher quit 
motivation and/or confidence in their ability to maintain abstinence during and after discharge 
without the support offered as part of our intervention. The failure of the present study to identify 
an effect of the enhanced intervention does not appear to be attributable to random differences in 
participant characteristics between the two treatment groups, as the two groups were closely 
matched on most variables, the only exception being a modest difference in Heaviness of Smoking 
Index which should, if anything, have favoured the intervention.  
 
Our findings are however consistent with the results of other attempts, in a wide range of settings, 
to prevent relapse among smokers who have quit (36). A Cochrane review of studies of relapse 
prevention found no evidence that interventions involving the delivery of behavioural support or 
pharmacotherapy were effective, though extending the period for which pharmacotherapy was used 
had some effect (36). The review included three studies of hospital inpatients (37-39) and involved 
adding support to cessation interventions less intensive than those used in the present study. It does 
not therefore follow that the relatively comprehensive intervention we used, as recommended by 
NICE, is responsible for the lack of effect of the relapse prevention package; rather, it appears that 
relapse prevention using the methods we tested, delivered once a smoker has commenced a quit 
attempt in hospital, is no more effective than existing support systems. In contrast to a number of 
previous studies, the present study ensured that all willing participants were discharged with a 
supply of NRT regardless of treatment group and thus the difference was largely in the delivery of 
additional behavioural support only, which may partly explain the lack of difference between groups. 
 
This study is subject to a number of limitations.  The recruitment rate was low, which limits the 
representativeness and generalisability of findings, although each group was demographically 
similar.  There was also a large loss to follow up which may have underestimated the effect of our 
intervention, however this rate was similar in both groups and so is unlikely to have biased the effect 
size achieved.  All components of the intervention were offered to all participants in the intervention 
arm. However, some of the participants did not have access to the internet or a smart phone which 
ruled out them being able to view websites or apps. The majority did not smoke indoors and so were 
not able to take-up the air monitoring component of the intervention. We cannot, therefore, be 
certain that intervention components would not be useful if fully implemented by smokers although 
stop smoking websites and apps were not rated as useful by the vast majority of participants who 
used them.   
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We did not collect data on abstinence from smoking whilst in hospital as participants may have felt 
obliged to deny smoking given the hospital smoke free policy, however smoking abstinence did not 
form part of our study eligibility criteria. The power calculation was based on an anticipated quit rate 
in the control group of 38%, which was achieved in our previous, similar study (10), and a potential 
increase in quit rate of 16% was calculated based on time and resource availability rather than an 
anticipated increase.  At 19%, the actual quit rate was lower than our estimate so power to detect a 
16% increase would have been lower than expected. As there was actually only a 2% difference 
between groups for our primary outcome, a lack of power is unlikely to explain our findings.  
 
Partcipants attended an average of 7.43 behavioural support sessions, lasting a median of 5.86 
weeks, however participants received an average of 3.84 weeks of NRT which is less than the 
minimum 4-weeks shown to be effective and may have contributed to the findings of this study.   
Given that two thirds of participants received more than 4-weeks of smoking cessation support, and 
around three quarters accepted the home visit we believe that the intervention was delivered 
largely as anticipated. However, only 46% of home visits were made within the 24-48 hour target 
time period specified in our protocol.  Despite this, there was no difference in quit rates between 
those that were seen within 48 hours and those who were not and thus we cannot be sure where 
the failure of the intervention occurred.  Adherence to the intervention appears to have been good 
and is unlikely to account for the lack of effect seen in this study.  We did not conduct a process 
evaluation and so cannot guarantee intervention fidelity and this should be a priority in future 
studies. 
 
Given the importance of smoking cessation to individual and public health, and the opportunity 
presented by admission to hospital to deliver effective interventions, it is essential that further 
research continues to address the intervention components and designs used to maximise their 
efficacy. For now however, our study indicates that cessation is more likely to be improved by 
working on measures to increase the currently low uptake of cessation support and retention in 
treatment by smokers admitted to hospital (40) than  bespoke packages intended to prevent 
relapse; and therefore that wider implementation of the NICE PH48 recommendations, rather than 
new developments in those recommendations, are the immediate healthcare priority in helping 
smokers who are admitted to hospital to quit.  
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